GFAP and frontotemporal dementia: Furthermore, the abundance of GFAP in the plasma of FTD patients, alone or in combination with the neurofilament light chain protein, revealed that the simultaneous assessment of these two proteins could serve as a differential diagnosis biomarker assay to discriminate between FTD and Alzheimer disease patients [66] as well as between molecularly distinct FTLD subtypes [67].